Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Sebastian

Showing results (181-190 of 183) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 183 results.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registryAlessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, et al.
Journal for Immunotherapy of Cancer|September 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registryAlessio Cortellini, Valentina Santo, Leonardo Brunetti, et al.
Pageof 19

Showing results (181-190 of 183) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 183 results.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Journal for Immunotherapy of Cancer|February 4, 2025
Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registryAlessio Cortellini, Leonardo Brunetti, Giuseppina Rita Di Fazio, et al.
Journal for Immunotherapy of Cancer|September 29, 2025
Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: insights from the pembrolizumab 5-year global registryAlessio Cortellini, Valentina Santo, Leonardo Brunetti, et al.
Pageof 19